Monocyte Release of Tumor Necrosis Factor-α and Interleukin-1β in Primary Type IIa and IIb Dyslipidemic Patients Treated With Statins or Fibrates

Both 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as well as peroxisome proliferator-activated receptor (PPAR)α activators (fibrates) proved to be effective in the primary and secondary prevention of cardiovascular diseases. The benefits of hypolipemic therapy in cardiovascular diseases cannot be explained only by the lipid-lowering potential of these agents. The aim of this study was to clarify the effect of hypolipemic agents on proinflammatory cytokine release from human monocytes in relationship with their action on plasma levels of sensitive systemic marker of low-grade vascular inflammation. Plasma lipid and high-sensitivity C-reactive protein (hsCRP) levels, and the release of tumor necrosis factor-α (TNFα) and interleukin-1β from monocytes were assessed at baseline and 30 and 90 days following randomization of IIa dyslipidemic patients into fluvastatin or simvastatin groups and randomization of type IIb dyslipidemic patients to the micronized form of either ciprofibrate or fenofibrate. Lipopolysaccharide-stimulated monocytes from dyslipidemic patients released significantly more TNFα (types IIa and IIb dyslipidemias) and interleukin-1β (type IIa dyslipidemia) in comparison with monocytes in 59 age-, sex-, and weight-matched control subjects. Their baseline hsCRP levels were also higher. Both statins and fibrates reduced the release of TNFα and interleukin-1β, and lowered plasma hsCRP levels. The effects of hypolipemic agents on cytokine release and plasma hsCRP were unrelated to their lipid-lowering action. Our results have demonstrated that type IIa and IIb dyslipidemic patients exhibit the abnormal pattern of TNFα and interleukin-1β production by activated monocytes. Both HMG-CoA reductase inhibitors and PPARα activators normalize monocytic secretion of these cytokines, and this action may partially contribute to the systemic antiinflammatory effect of hypolipemic agents. The statin- and fibrate-induced suppression of proinflammatory cytokine release from monocytes seems to play a role in their beneficial effect on the incidence of cardiovascular events.

[1]  G. Hunninghake,et al.  Inhibition of Rho Family GTPases Results in Increased TNF-α Production After Lipopolysaccharide Exposure 1 , 2003, The Journal of Immunology.

[2]  B. Okopień,et al.  Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia , 2003, European Journal of Clinical Pharmacology.

[3]  D. Gómez-Coronado,et al.  Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells. , 2000, Atherosclerosis.

[4]  Tzung-Dau Wang,et al.  Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. , 2003, Atherosclerosis.

[5]  Y. Horsmans,et al.  Clinical Pharmacokinetics of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors , 1996, Clinical pharmacokinetics.

[6]  Michael R. Müller,et al.  Simvastatin Reduces Expression of Cytokines Interleukin-6, Interleukin-8, and Monocyte Chemoattractant Protein-1 in Circulating Monocytes From Hypercholesterolemic Patients , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[7]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[8]  M. Haberka,et al.  Effect of Monthly Atorvastatin and Fenofibrate Treatment on Monocyte Chemoattractant Protein-1 Release in Patients with Primary Mixed Dyslipidemia , 2005, Journal of cardiovascular pharmacology.

[9]  Robert Kleemann,et al.  Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. , 2003, Blood.

[10]  Robert Kleemann,et al.  Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. , 2004, Blood.

[11]  A. Wessel,et al.  Interleukin-1 and related proteins in cardiovascular disease in adults and children. , 2001, Shock.

[12]  S. Frøland,et al.  Increased Expression of Interleukin-1 in Coronary Artery Disease With Downregulatory Effects of HMG-CoA Reductase Inhibitors , 2004, Circulation.

[13]  S. Janciauskiene,et al.  Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. , 2002, Pharmacological research.

[14]  R. Mortensen.  C-reactive protein, inflammation, and innate immunity , 2001, Immunologic research.

[15]  J. Hallenbeck.  The many faces of tumor necrosis factor in stroke , 2002, Nature Medicine.

[16]  J. Spence,et al.  Clinical Pharmacokinetics of Fibric Acid Derivatives (Fibrates) , 1998, Clinical pharmacokinetics.

[17]  Shuiping Zhao,et al.  Gemfibrozil reduces release of tumor necrosis factor-alpha in peripheral blood mononuclear cells from healthy subjects and patients with coronary heart disease. , 2003, Clinica chimica acta; international journal of clinical chemistry.

[18]  H. Waterham,et al.  Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome. , 2002, Arthritis and rheumatism.

[19]  T. Awata,et al.  Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. , 2000, Life sciences.

[20]  S. Basili,et al.  Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. , 2000, Journal of the American College of Cardiology.

[21]  Robert Kleemann,et al.  Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFκB-C/EBP-β complex formation , 2003 .

[22]  K. Arnesen,et al.  Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. , 2003, Journal of the American College of Cardiology.

[23]  P. Libby,et al.  Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. , 2004, The American journal of medicine.

[24]  O. Grip,et al.  Pravastatin down-regulates inflammatory mediators in human monocytes in vitro. , 2000, European journal of pharmacology.

[25]  K. Labuzek,et al.  The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia. , 2004, Atherosclerosis.

[26]  A. Terashi,et al.  Effects of an HMG-CoA reductase inhibitor on cytokine production by human monocytes/macrophages. , 1995, Nihon Ika Daigaku zasshi.

[27]  A. Weverling-Rijnsburger,et al.  Hyperlipoproteinemia affects cytokine production in whole blood samples ex vivo. The influence of lipid-lowering therapy. , 2000, Atherosclerosis.

[28]  E. Yeh,et al.  Inflammatory Cytokines Stimulated C-Reactive Protein Production by Human Coronary Artery Smooth Muscle Cells , 2003, Circulation.

[29]  M. Netea,et al.  LPS-induced cytokine production and expression of LPS-receptors by peripheral blood mononuclear cells of patients with familial hypercholesterolemia and the effect of HMG-CoA reductase inhibitors. , 1998, Atherosclerosis.

[30]  J. Berger,et al.  Activation of PPARα or γ Reduces Secretion of Matrix Metalloproteinase 9 but Not Interleukin 8 from Human Monocytic THP-1 Cells , 2000 .

[31]  G. Zhou,et al.  Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. , 2000, Biochemical and biophysical research communications.

[32]  Jian‐Jun Li,et al.  Simvastatin inhibits interleukin‐6 release in human monocytes stimulated by C‐reactive protein and lipopolysaccharide , 2003, Coronary artery disease.

[33]  T. Meinertz,et al.  Zytokine in der Pathogenese der Atherosklerose , 2002, Deutsche medizinische Wochenschrift.

[34]  P. M. Davis,et al.  Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. , 2001, International immunopharmacology.

[35]  B. Binder,et al.  Simvastatin Reduces the Expression of Adhesion Molecules in Circulating Monocytes From Hypercholesterolemic Patients , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[36]  O. Grip,et al.  Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes. , 2002, Inflammation research : official journal of the European Histamine Research Society ... [et al.].